Plasma Concentrations of Remdesivir Metabolite in a Critical COVID-19 Patient Needing Continuous Venovenous Haemodialysis
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Andre E, Lemaitre F, Verdier M, Haufroid V, Pinto Pereira J, Hantson P Case Rep Crit Care. 2024; 2024:6631866.
PMID: 38435396 PMC: 10904205. DOI: 10.1155/2024/6631866.
Coggins S, Kimble B, Malik R, Thompson M, Norris J, Govendir M Vet Q. 2024; 44(1):1-9.
PMID: 38288972 PMC: 10829815. DOI: 10.1080/01652176.2024.2305731.
References
1.
Avataneo V, De Nicolo A, Cusato J, Antonucci M, Manca A, Palermiti A
. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. J Antimicrob Chemother. 2020; 75(7):1772-1777.
PMC: 7197584.
DOI: 10.1093/jac/dkaa152.
View
2.
Sorgel F, Malin J, Hagmann H, Kinzig M, Bilal M, Eichenauer D
. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. J Antimicrob Chemother. 2020; 76(3):825-827.
PMC: 7799013.
DOI: 10.1093/jac/dkaa500.
View
3.
Le M, Le Hingrat Q, Jaquet P, Wicky P, Bunel V, Massias L
. Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19. Antimicrob Agents Chemother. 2020; 64(11).
PMC: 7577145.
DOI: 10.1128/AAC.01521-20.
View
4.
Adamsick M, Gandhi R, Bidell M, Elshaboury R, Bhattacharyya R, Kim A
. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. J Am Soc Nephrol. 2020; 31(7):1384-1386.
PMC: 7351006.
DOI: 10.1681/ASN.2020050589.
View
5.
Wise J
. Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency. BMJ. 2020; 369:m2610.
DOI: 10.1136/bmj.m2610.
View